SOLID BIOSCIENCES—$SLDB CASHES UP FOR GENE THERAPY PUSH
SOLID BIOSCIENCES—
SLDB CASHES UP FOR GENE THERAPY PUSH
(1/9)
Good afternoon, Tradingview! Solid Biosciences is stacking cash—no revenue yet, but a 200M raise has tongues wagging 📈🔥.SLDB’s betting big on gene therapy—here’s the scoop! 🚀
(2/9) – CASH, NOT SALES
• Revenue: Zilch—clinical-stage vibes 💥
• Q3 ‘24 Loss: 0.61/share, missed $0.58 est. 📊
• Cash Boost: 200M offering just landed
No sales, butSLDB’s war chest is growing!
(3/9) – BIG MOVE
• Feb 18 Raise: 200M via 35.7M shares, warrants 🌍
• Cash Pile: Was 171M, now nearing 350M 🚗
• Goal: Fuel SGT-003 trials into ‘27 🌟
SLDB’s loading up for the long haul!
(4/9) – SECTOR CHECK
• Market Cap: 500M post-raise 📈
• Vs. Peers: Sarepta’s 13B dwarfs it—revenue rules
• Edge: Low EV (150M), big therapy dreams
Undervalued biotech bet or long shot? 🌍
(5/9) – RISKS ON DECK
• Trials: SGT-003 flops could sink it ⚠️
• Sentiment: 30% drop from Jan peak—jitters 🏛️
• Burn: $20-25M/quarter—clock’s ticking 📉
High stakes, high risks—can it deliver?
(6/9) – SWOT: STRENGTHS
• Cash: 200M raise powers trials 🌟
• SGT-003: Early data dazzles, Fast Track nod 🔍
• DMD Focus: Huge need, blockbuster shot 🚦
SLDB’s got fuel and firepower!
(7/9) – SWOT: WEAKNESSES & OPPORTUNITIES
• Weaknesses: No revenue, all-in on one play 💸
• Opportunities: $2-4B cap if trials pop 🌍
CanSLDB turn cash into a cure?
(8/9) –SLDB’s 200M haul—your take?
1️⃣ Bullish—Gene therapy gold ahead.
2️⃣ Neutral—Wait for trial proof.
3️⃣ Bearish—Risks outweigh the buzz.
Vote below! 🗳️👇
(9/9) – FINAL TAKEAWAY
SLDB’s revenue-free, but 200M keeps SGT-003 alive—stock’s buzzing 🌍🪙. Low EV vs. peers, yet trials and rivals loom. Cure or bust?
SLDB CASHES UP FOR GENE THERAPY PUSH(1/9)
Good afternoon, Tradingview! Solid Biosciences is stacking cash—no revenue yet, but a 200M raise has tongues wagging 📈🔥.
SLDB’s betting big on gene therapy—here’s the scoop! 🚀 (2/9) – CASH, NOT SALES
• Revenue: Zilch—clinical-stage vibes 💥
• Q3 ‘24 Loss: 0.61/share, missed $0.58 est. 📊
• Cash Boost: 200M offering just landed
No sales, but
SLDB’s war chest is growing! (3/9) – BIG MOVE
• Feb 18 Raise: 200M via 35.7M shares, warrants 🌍
• Cash Pile: Was 171M, now nearing 350M 🚗
• Goal: Fuel SGT-003 trials into ‘27 🌟
SLDB’s loading up for the long haul! (4/9) – SECTOR CHECK
• Market Cap: 500M post-raise 📈
• Vs. Peers: Sarepta’s 13B dwarfs it—revenue rules
• Edge: Low EV (150M), big therapy dreams
Undervalued biotech bet or long shot? 🌍
(5/9) – RISKS ON DECK
• Trials: SGT-003 flops could sink it ⚠️
• Sentiment: 30% drop from Jan peak—jitters 🏛️
• Burn: $20-25M/quarter—clock’s ticking 📉
High stakes, high risks—can it deliver?
(6/9) – SWOT: STRENGTHS
• Cash: 200M raise powers trials 🌟
• SGT-003: Early data dazzles, Fast Track nod 🔍
• DMD Focus: Huge need, blockbuster shot 🚦
SLDB’s got fuel and firepower! (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES
• Weaknesses: No revenue, all-in on one play 💸
• Opportunities: $2-4B cap if trials pop 🌍
Can
SLDB turn cash into a cure? (8/9) –
SLDB’s 200M haul—your take?1️⃣ Bullish—Gene therapy gold ahead.
2️⃣ Neutral—Wait for trial proof.
3️⃣ Bearish—Risks outweigh the buzz.
Vote below! 🗳️👇
(9/9) – FINAL TAKEAWAY
SLDB’s revenue-free, but 200M keeps SGT-003 alive—stock’s buzzing 🌍🪙. Low EV vs. peers, yet trials and rivals loom. Cure or bust? 
⚡️ Request a trial or subscribe to our premium🛠️tools at ➡️DCAlpha.net
All scripts & content provided by DCAChampion are for informational & educational purposes only.
All scripts & content provided by DCAChampion are for informational & educational purposes only.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
⚡️ Request a trial or subscribe to our premium🛠️tools at ➡️DCAlpha.net
All scripts & content provided by DCAChampion are for informational & educational purposes only.
All scripts & content provided by DCAChampion are for informational & educational purposes only.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.